Connect Biopharma's Rademikibart Phase 3 Data for Atopic Dermatitis to Debut at AAD 2026 — Connect Biopharma Holdings Limited

Event summary

Phase 3 study results of rademikibart in moderate-to-severe atopic dermatitis to be presented at the 2026 AAD Annual Meeting on March 28.
Study conducted by Connect Biopharma's partner Simcere Pharmaceutical in China.
Connect Biopharma eligible for up to $110 million in milestone payments and low double-digit royalties on net sales in Greater China.
Rademikibart targets IL-4Rα, blocking IL-4 and IL-13 pathways for Th2-related inflammatory diseases.

The big picture

Connect Biopharma's focus remains on asthma and COPD, but the positive Phase 3 data for rademikibart in atopic dermatitis opens a new strategic avenue. The presentation at AAD 2026 underscores the drug's potential as a differentiated therapy in the dermatology space, while the partnership with Simcere provides a financial lifeline through milestone payments and royalties. The biopharmaceutical industry continues to prioritize multi-indication drugs, and rademikibart's success in atopic dermatitis could enhance its valuation and attractiveness to potential partners.

What we're watching

Regulatory Approval: Whether Simcere's pending NDA for rademikibart in China will receive approval by the NMPA and the timing of any such approval.
Market Expansion: The potential for Connect Biopharma to target atopic dermatitis as a future indication outside of China based on the Phase 3 study results.
Financial Upside: The pace at which Connect Biopharma can achieve remaining milestone payments and royalties from Simcere's commercialization of rademikibart in Greater China.